<DOC>
	<DOCNO>NCT00539032</DOCNO>
	<brief_summary>This study conduct among child Saudi Arabia previously receive two dos A , C , Y , W-135 polysaccharide vaccine age 2 year , meningococcal vaccine-naïve child ( Control Group ) . This study evaluate administration Menactra® term serum bactericidal antibody induces two study group . Safety Menactra® vaccine described .</brief_summary>
	<brief_title>Immunology Safety Menactra® Children Saudi Arabia</brief_title>
	<detailed_description />
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria : Healthy , determine medical history physical examination . Aged 5 8 year day inclusion ( 5th birthday 1 day 9th birthday inclusive ) . For Booster Group , two dos quadrivalent ( A , C , Y , W135 ) meningococcal polysaccharide vaccine receive age 2 year For Control Group , previous history meningococcal vaccination Informed consent form sign parent ( ) legal representative Able provide vaccination log available vaccination record Health Center . Able attend schedule visit comply trial procedure Exclusion Criteria : Serious chronic disease ( i.e. , cardiac , renal , neurologic , metabolic , rheumatologic , psychiatric , etc . ) Known suspect impairment immunologic function . Acute medical illness without fever within last 72 hour oral temperature ≥ 37.5°C time inclusion . Administration immune globulin blood product within last three month , injected oral corticosteroid immunomodulatory therapy within six week trial vaccine . Individuals taper dose schedule oral steroid last &lt; 7 day may include trial provide received one course within last two week prior enrollment . Oral inject antibiotic therapy within 72 hour prior vaccination . Received vaccine 14day period prior trial vaccination , schedule receive vaccination 14day period trial vaccination . Previous history document invasive meningococcal disease . For Control Group , previous history meningococcal vaccination . Systemic hypersensitivity vaccine component history lifethreatening reaction trial vaccine vaccine contain substance . Participation another clinical trial 4 week precede trial vaccination Planned participation another clinical trial present trial period Any condition , , opinion investigator , would pose health risk subject , interfere evaluation vaccine . Personal family history Guillain Barré syndrome .</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>8 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>N. meningitidis</keyword>
	<keyword>Meningitis</keyword>
	<keyword>Meningococcemia</keyword>
</DOC>